AU Patent

AU2022299169A1 — Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Assigned to Beth Israel Deaconess Medical Center Inc · Expires 2024-02-08 · 2y expired

What this patent protects

Patent listed against inclisiran-sodium.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: AU2022299169A1
Jurisdiction: AU
Classification: —
Expires: 2024-02-08
Drug substance claim: No
Drug product claim: No
Assignee: Beth Israel Deaconess Medical Center Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.